Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2007;38:1345-1353
Published online before print March 1, 2007, doi: 10.1161/01.STR.0000259709.16654.8f
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/4/1345    most recent
01.STR.0000259709.16654.8fv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dimitrijevic, O. B.
Right arrow Articles by Andjelkovic, A. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dimitrijevic, O. B.
Right arrow Articles by Andjelkovic, A. V.
Related Collections
Right arrow Animal models of human disease
Right arrow Acute Cerebral Infarction
Right arrow Pathology of Stroke

(Stroke. 2007;38:1345.)
© 2007 American Heart Association, Inc.


Original Contributions

Absence of the Chemokine Receptor CCR2 Protects Against Cerebral Ischemia/Reperfusion Injury in Mice

Oliver B. Dimitrijevic, MD; Svetlana M. Stamatovic, MD, PhD; Richard F. Keep, PhD Anuska V. Andjelkovic, MD, PhD

From the Departments of Pathology (O.B.D., S.M.S., A.V.A.), Neurosurgery (R.F.K., A.V.A.), and Integrative and Molecular Physiology (R.F.K.), University of Michigan, Medical School, Ann Arbor.

Correspondence to Anuska V. Andjelkovic, Department of Pathology, University of Michigan, 7520 MSRB I, Ann Arbor, MI 48109-0532. E-mail anuskaa{at}umich.edu

Background and Purpose— The chemokine, monocyte chemoattractant protein-1 (CCL2), is a major factor driving leukocyte infiltration into the brain parenchyma in a variety of neuropathologic conditions associated with inflammation, including stroke. In addition, recent studies indicate that CCL2 and its receptor (CCR2) could have an important role in regulating blood-brain barrier (BBB) permeability. This study evaluated the role of the CCL2/CCR2 axis in regulating postischemic inflammation, BBB breakdown, and vasogenic edema formation.

Methods— CCR2–/– and CCR2+/+ mice were subjected to focal transient cerebral ischemia. BBB permeability and brain edema formation were observed at days 1 and 5 of reperfusion by evaluating the product surface area for fluorescein isothiocyanate–albumin and measuring water and electrolyte contents. Immunohistochemistry was used to assess leukocyte infiltration. cDNA gene and protein arrays for inflammatory cytokines were used to assess inflammatory profiles in CCR2+/+ and CCR2–/– mice.

Results— CCR2–/– mice had reduced infarct sizes and significantly reduced BBB permeability and brain edema formation in the affected ischemic hemisphere compared with CCR2+/+ mice. This reduction in injury was closely associated with reduced infiltration of not only monocytes but also neutrophils (7- and 4-fold decreases, respectively). In addition, CCR2–/– mice had reduced expression/production of inflammatory cytokines during reperfusion.

Conclusions— These data suggest that inhibiting the CCL2/CCR2 axis affects brain reperfusion outcome by reducing brain edema, leukocyte infiltration, and inflammatory mediator expression.


Key Words: blood-brain barrier permeability • CCL2 • chemokines • inflammation • stroke




This article has been cited by other articles:


Home page
J. Immunol.Home page
W.-Y. Chen and M.-S. Chang
IL-20 Is Regulated by Hypoxia-Inducible Factor and Up-Regulated after Experimental Ischemic Stroke
J. Immunol., April 15, 2009; 182(8): 5003 - 5012.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
D. Sun, C. O. Martinez, O. Ochoa, L. Ruiz-Willhite, J. R. Bonilla, V. E. Centonze, L. L. Waite, J. E. Michalek, L. M. McManus, and P. K. Shireman
Bone marrow-derived cell regulation of skeletal muscle regeneration
FASEB J, February 1, 2009; 23(2): 382 - 395.
[Abstract] [Full Text] [PDF]


Home page
Therapeutic Advances in Neurological DisordersHome page
D. M. Hermann
Review: Future perspectives for brain pharmacotherapies: implications of drug transport processes at the blood--brain barrier
Therapeutic Advances in Neurological Disorders, November 1, 2008; 1(3): 167 - 179.
[Abstract] [PDF]


Home page
StrokeHome page
J. Iwanami, M. Mogi, J.-M. Li, K. Tsukuda, L.-J. Min, A. Sakata, T. Fujita, M. Iwai, and M. Horiuchi
Deletion of Angiotensin II Type 2 Receptor Attenuates Protective Effects of Bone Marrow Stromal Cell Treatment on Ischemia-Reperfusion Brain Injury in Mice * Supplemental Materials and Methods
Stroke, September 1, 2008; 39(9): 2554 - 2559.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
S. Terao, G. Yilmaz, K. Y. Stokes, J. Russell, M. Ishikawa, T. Kawase, and D. N. Granger
Blood Cell-Derived RANTES Mediates Cerebral Microvascular Dysfunction, Inflammation, and Tissue Injury After Focal Ischemia-Reperfusion
Stroke, September 1, 2008; 39(9): 2560 - 2570.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Goerge, B. Ho-Tin-Noe, C. Carbo, C. Benarafa, E. Remold-O'Donnell, B.-Q. Zhao, S. M. Cifuni, and D. D. Wagner
Inflammation induces hemorrhage in thrombocytopenia
Blood, May 15, 2008; 111(10): 4958 - 4964.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
E. Kim, A. T. Tolhurst, L. Y. Qin, X.-Y. Chen, M. Febbraio, and S. Cho
CD36/Fatty Acid Translocase, An Inflammatory Mediator, Is Involved in Hyperlipidemia-Induced Exacerbation in Ischemic Brain Injury
J. Neurosci., April 30, 2008; 28(18): 4661 - 4670.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. A. Elmarakby, J. E. Quigley, J. J. Olearczyk, A. Sridhar, A. K. Cook, E. W. Inscho, D. M. Pollock, and J. D. Imig
Chemokine Receptor 2b Inhibition Provides Renal Protection in Angiotensin II Salt Hypertension
Hypertension, December 1, 2007; 50(6): 1069 - 1076.
[Abstract] [Full Text] [PDF]